TY - JOUR
T1 - Identification of PCPE-2 as the endogenous specific inhibitor of human BMP-1/tolloid-like proteinases
AU - Vadon-Le Goff, Sandrine
AU - Tessier, Agnès
AU - Napoli, Manon
AU - Dieryckx, Cindy
AU - Bauer, Julien
AU - Dussoyer, Mélissa
AU - Lagoutte, Priscillia
AU - Peyronnel, Célian
AU - Essayan, Lucie
AU - Kleiser, Svenja
AU - Tueni, Nicole
AU - Bettler, Emmanuel
AU - Mariano, Natacha
AU - Errazuriz-Cerda, Elisabeth
AU - Fruchart Gaillard, Carole
AU - Ruggiero, Florence
AU - Becker-Pauly, Christoph
AU - Allain, Jean Marc
AU - Bruckner-Tuderman, Leena
AU - Nyström, Alexander
AU - Moali, Catherine
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12/1
Y1 - 2023/12/1
N2 - BMP-1/tolloid-like proteinases (BTPs) are major players in tissue morphogenesis, growth and repair. They act by promoting the deposition of structural extracellular matrix proteins and by controlling the activity of matricellular proteins and TGF-β superfamily growth factors. They have also been implicated in several pathological conditions such as fibrosis, cancer, metabolic disorders and bone diseases. Despite this broad range of pathophysiological functions, the putative existence of a specific endogenous inhibitor capable of controlling their activities could never be confirmed. Here, we show that procollagen C-proteinase enhancer-2 (PCPE-2), a protein previously reported to bind fibrillar collagens and to promote their BTP-dependent maturation, is primarily a potent and specific inhibitor of BTPs which can counteract their proteolytic activities through direct binding. PCPE-2 therefore differs from the cognate PCPE-1 protein and extends the possibilities to fine-tune BTP activities, both in physiological conditions and in therapeutic settings.
AB - BMP-1/tolloid-like proteinases (BTPs) are major players in tissue morphogenesis, growth and repair. They act by promoting the deposition of structural extracellular matrix proteins and by controlling the activity of matricellular proteins and TGF-β superfamily growth factors. They have also been implicated in several pathological conditions such as fibrosis, cancer, metabolic disorders and bone diseases. Despite this broad range of pathophysiological functions, the putative existence of a specific endogenous inhibitor capable of controlling their activities could never be confirmed. Here, we show that procollagen C-proteinase enhancer-2 (PCPE-2), a protein previously reported to bind fibrillar collagens and to promote their BTP-dependent maturation, is primarily a potent and specific inhibitor of BTPs which can counteract their proteolytic activities through direct binding. PCPE-2 therefore differs from the cognate PCPE-1 protein and extends the possibilities to fine-tune BTP activities, both in physiological conditions and in therapeutic settings.
U2 - 10.1038/s41467-023-43401-0
DO - 10.1038/s41467-023-43401-0
M3 - Article
C2 - 38049428
AN - SCOPUS:85178489790
SN - 2041-1723
VL - 14
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 8020
ER -